Quince Therapeutics, Inc.(formerly Cortexyme, Inc.） is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. Its pipeline composed of COR388, COR588, COR788, COR822, and Coronavirus 3CL protease inhibitor. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.
相关临床试验
12
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2012
已完成
6
50.0%
招募中
3
25.0%
终止
3
25.0%
暂无批准数据
- Quince Therapeutics announced positive Phase 2a results for LAM-001, an inhaled rapamycin formulation, showing clinically meaningful improvements in patients with pulmonary hypertension associated with interstitial lung disease. - The 24-week study demonstrated a 67.4-meter improvement in six-minute walk distance and a 33.9% reduction in pulmonary vascular resistance in PH-ILD patients receiving LAM-001 as add-on therapy. - Based on these encouraging results, the company plans to initiate a Phase 2b trial in PH-ILD in mid-2026, with topline data expected in the first quarter of 2028. - LAM-001 targets the mTOR pathway to address both vascular remodeling and progressive fibrosis, offering potential as a disease-modifying therapy for approximately 86,000 U.S. patients with PH-ILD.
- Quince Therapeutics acquired Orphai Therapeutics and secured up to $187 million in financing to advance LAM-001, an inhaled rapamycin formulation targeting multiple rare pulmonary diseases. - LAM-001 demonstrated promising Phase 2a data in pulmonary hypertension associated with interstitial lung disease, with a Phase 2b trial planned for mid-2026 and results expected in Q1 2028. - The acquisition brings three clinical programs targeting approximately 274,000 patients across the U.S. and Europe, including PH-ILD, bronchiolitis obliterans syndrome, and sarcoidosis-associated pulmonary hypertension. - The combined financing and existing cash are expected to fund operations through 2028, supporting multiple clinical milestones across the expanded pulmonary pipeline.
- Quince Therapeutics has engaged LifeSci Capital as its exclusive financial advisor to explore strategic alternatives aimed at maximizing shareholder value. - The company is considering various options including partnerships, joint ventures, mergers, acquisitions, and licensing deals, as well as restructuring of liabilities. - The strategic review announcement triggered explosive stock movement, with shares surging over 300% and trading volume exceeding 1.1 billion shares. - Quince focuses on precision therapeutics for rare diseases through its bone-targeting drug platform that delivers therapeutics directly to fracture and disease sites.
- Quince Therapeutics announced positive safety review results from an independent data and safety monitoring board for its Phase 3 NEAT trial of eDSP in Ataxia-Telangiectasia patients. - The monitoring board found no safety concerns and recommended continuation of the study without modifications, supporting eDSP's favorable safety profile. - The company remains on track to report topline results from the pivotal trial in the first quarter of 2026 for what could be the first-to-market A-T treatment. - eDSP uses proprietary AIDE technology to encapsulate dexamethasone in patients' own red blood cells, designed to provide corticosteroid efficacy while reducing adverse effects.
- Quince Therapeutics has formed a strategic partnership with Option Care Health to support the commercial development of encapsulated dexamethasone sodium phosphate (eDSP) for Ataxia-Telangiectasia treatment. - The collaboration leverages Option Care Health's network of 90+ specialty pharmacies and 180+ ambulatory infusion suites to provide nationwide access to eDSP administration. - eDSP is currently in Phase 3 NEAT trial with 105 patients enrolled and topline results expected in Q1 2026, potentially becoming the first approved therapy for A-T. - The partnership positions Quince to scale into additional rare disease markets, including Duchenne muscular dystrophy, while reducing operational complexity and costs.
- Quince Therapeutics appointed Dr. Hassan Abolhassani, a top-cited immunologist from Karolinska Institutet, to its Scientific Advisory Board as the ninth expert member. - The appointment comes as the company prepares to report topline results from its pivotal Phase 3 trial of eDSP for Ataxia-Telangiectasia in Q1 2026. - Dr. Abolhassani brings specialized expertise in immunodeficiency disorders and Ataxia-Telangiectasia, supporting Quince's expansion into multiple rare disease indications. - The company is exploring eDSP for 11 additional rare diseases where corticosteroid treatment could be beneficial without safety concerns.
- Quince Therapeutics raised $11.5 million in upfront proceeds with potential for an additional $10.4 million through warrant exercises to fund operations into 2026. - The financing will primarily support enrollment in the company's pivotal Phase 3 NEAT clinical trial evaluating eDSP for Ataxia-Telangiectasia treatment. - Healthcare-focused institutional investor Nantahala Capital led the private placement, with participation from existing stockholders and company management. - The securities were priced at a 10% premium to the previous closing price, reflecting investor confidence in the rare disease-focused biotechnology company.
- Quince Therapeutics has enrolled 46 participants in its Phase 3 NEAT trial evaluating EryDex for Ataxia-Telangiectasia treatment, with completion expected in Q2 2025 and topline results by year-end. - The pivotal trial, conducted under FDA Special Protocol Assessment, aims to enroll 86 patients aged 6-9 years and 20 patients aged 10 or older to evaluate EryDex's neurological effects. - An open-label extension study has been initiated with 17 participants from the U.S., U.K., and European Union already transitioning from the main trial.
- Quince Therapeutics' Phase 3 NEAT trial of EryDex for Ataxia-Telangiectasia (A-T) is expected to complete enrollment in Q2 2025, marking a significant milestone. - Topline results from the international, multi-center NEAT trial, evaluating EryDex's neurological effects in A-T patients, are anticipated in Q4 2025. - EryDex, an investigational drug/device combination, targets A-T, a rare pediatric neurodegenerative disease affecting approximately 4,600 diagnosed patients in the U.S. - Quince Therapeutics plans to initiate a Phase 2 trial of EryDex for Duchenne muscular dystrophy (DMD) in 2025, expanding its therapeutic potential.
- Quince Therapeutics presented safety data from the Phase 3 ATTeST trial of EryDex for Ataxia-Telangiectasia (A-T) at the Child Neurology Society Annual Meeting. - The study found EryDex was generally well-tolerated, with most treatment-emergent adverse events (TEAEs) being mild to moderate and transient, similar to placebo. - Typical steroid-related side effects were not observed, suggesting a favorable safety profile for intra-erythrocyte dexamethasone sodium phosphate. - Quince is currently enrolling patients in the pivotal Phase 3 NEAT trial, with topline results expected in the fourth quarter of 2025.
